CHICAGO TRUST Co NA Has $1.42 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

CHICAGO TRUST Co NA boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 67.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,236 shares of the medical device company’s stock after purchasing an additional 7,373 shares during the quarter. CHICAGO TRUST Co NA’s holdings in DexCom were worth $1,418,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. B. Riley Wealth Advisors Inc. raised its stake in DexCom by 4.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock valued at $445,000 after purchasing an additional 162 shares in the last quarter. Crossmark Global Holdings Inc. boosted its position in shares of DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after acquiring an additional 182 shares in the last quarter. Perennial Investment Advisors LLC boosted its holdings in shares of DexCom by 7.4% in the 2nd quarter. Perennial Investment Advisors LLC now owns 3,156 shares of the medical device company’s stock valued at $358,000 after purchasing an additional 217 shares in the last quarter. Riverview Trust Co lifted its position in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares during the last quarter. Finally, Koa Wealth Management LLC raised its stake in DexCom by 7.7% during the third quarter. Koa Wealth Management LLC now owns 3,770 shares of the medical device company’s stock worth $253,000 after acquiring an additional 270 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.30% of the company’s stock.

DexCom Stock Performance

Shares of NASDAQ DXCM traded down $1.60 during mid-day trading on Monday, hitting $76.16. The company had a trading volume of 1,732,142 shares, compared to its average volume of 2,792,768. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $29.75 billion, a price-to-earnings ratio of 45.61, a P/E/G ratio of 2.36 and a beta of 1.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock’s 50-day moving average price is $76.93 and its 200-day moving average price is $78.84.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Raymond James dropped their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada cut their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company boosted their target price on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Finally, Sanford C. Bernstein raised their price objective on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average price target of $98.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.